Antimicrobiology in Epidemiology
Antimicrobial resistance has become a serious healthcare problem, with high resistance rates of most common bacteria to clinically important antimicrobial agents. Resistance has emerged to even the newer, almost potent antimicrobial agents. Methicillin-resistant S. aureus, ESBL-producing Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii represent more than 50% of microbial isolates. Furthermore, bacterial resistance to fluoroquinolones, macrolides and third-generation cephalosporins is of serious concern. The molecular epidemiology and resistance mechanisms of the antimicrobial strains exhibited regional specificity, as well as the influence of dissemination of international clonal complexes.
Related Conference of Antimicrobiology in Epidemiology
10th International Conference on Vaccines, Immunology and Clinical Trials
8th International conference on Vaccines, Vaccination and Immunization
Antimicrobiology in Epidemiology Conference Speakers
Recommended Sessions
- Antibiotics, Antimicrobial & Chemotherapy
- Antimicrobial Pathogens : Alternative Approaches
- Antimicrobials
- Antimicrobiology in Epidemiology
- COVID 19 in Antimicrobial and Antibacterial Agents
- Global Spread of Viruses
- Immunity , Infection Diseases and Agents
- Microbial Immunology
- Microbial Physiology and Metabolism
- Microorganisms in Recent Drug Discovery
- Pharmaceutical microbiology
- Pharmalogical Consideration of Infectious Disease and Agents
- Vaccine and Vaccination
- Vaccines and Therapeutics
Related Journals
Are you interested in
- Adaptive Immunity and Immune Regulation - Vaccines R&D 2027 (France)
- Advanced Vaccine Research and Innovation - VACCINE CONGRESS 2026 (Japan)
- Allergy and Clinical Immunology - Vaccines R&D 2027 (France)
- Artificial Intelligence in Vaccine Discovery - Vaccines R&D 2027 (France)
- Artificial Intelligence in Vaccine Research - VACCINE CONGRESS 2026 (Japan)
- Autoimmunity and Immune Disorders - Vaccines R&D 2027 (France)
- Bioinformatics and AI in Vaccine Design - Vaccine Immunology 2026 (Canada)
- Bioinformatics and Computational Immunology - Vaccines R&D 2027 (France)
- Biomarkers in Immunology and Clinical Research - Vaccines R&D 2027 (France)
- Biostatistics and Epidemiology in Vaccine Research - VACCINE CONGRESS 2026 (Japan)
- Biotechnology and Vaccine Engineering - VACCINE CONGRESS 2026 (Japan)
- Cancer Vaccines and Immunotherapy - Vaccines R&D 2027 (France)
- Challenges in Vaccine Accessibility and Equity - Vaccine Immunology 2026 (Canada)
- Clinical Trial Design and Regulatory Affairs - Vaccines R&D 2027 (France)
- Clinical Trials and Vaccine Evaluation - VACCINE CONGRESS 2026 (Japan)
- Clinical Trials in Vaccinology - Vaccines R&D 2027 (France)
- Clinical Vaccinology and Immunization Practice - VACCINE CONGRESS 2026 (Japan)
- Clinical Vaccinology and Immunotherapy - Vaccine Immunology 2026 (Canada)
- Digital Health in Clinical Trials - Vaccines R&D 2027 (France)
- Emerging & Re-emerging Infectious Diseases - Vaccines R&D 2027 (France)
- Emerging Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Emerging Trends in Vaccine Science - VACCINE CONGRESS 2026 (Japan)
- Ethical, Legal and Regulatory Aspects of Clinical Research - Vaccines R&D 2027 (France)
- Future Directions in Vaccine Research - Vaccine Immunology 2026 (Canada)
- Global Health and Vaccine Equity - VACCINE CONGRESS 2026 (Japan)
- Global Vaccination Programs and Public Health - Vaccines R&D 2027 (France)
- Global Vaccination Strategies - Vaccine Immunology 2026 (Canada)
- Human Microbiome and Vaccines - Vaccine Immunology 2026 (Canada)
- Immunogenetics and Genomic Medicine - Vaccines R&D 2027 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (Canada)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (Canada)
- Immunology and Host Immune Response - VACCINE CONGRESS 2026 (Japan)
- Immunology and Immune System Innovations - Vaccine Immunology 2026 (Canada)
- Immunology and Immune System Mechanisms - Vaccines R&D 2027 (France)
- Immunology of Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Immunotherapy and Vaccines for Non-Infectious Diseases - Vaccine Immunology 2026 (Canada)
- Immunotherapy in Cancer Treatment - Vaccine Immunology 2026 (Canada)
- Industrial Vaccine Manufacturing and Scale Up - VACCINE CONGRESS 2026 (Japan)
- Industry and Technology Innovations - Vaccine Immunology 2026 (Canada)
- Infectious Diseases and Immunization Strategies - Vaccines R&D 2027 (France)
- Innovations in Vaccines, Immunology and Clinical Trials - Vaccines R&D 2027 (France)
- Maternal, Neonatal, and Geriatric Immunization - Vaccine Immunology 2026 (Canada)
- Microbiome-Targeted Vaccines - Vaccine Immunology 2026 (Canada)
- Monoclonal Antibodies and Biologics - Vaccines R&D 2027 (France)
- mRNA, DNA & Viral Vector Vaccines - Vaccines R&D 2027 (France)
- Mucosal and Innate Immunity - Vaccines R&D 2027 (France)
- Nanotechnology and Advanced Delivery Systems - Vaccine Immunology 2026 (Canada)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2026 (Japan)
- Nanotechnology in Vaccine Delivery - Vaccine Immunology 2026 (Canada)
- Next Generation Vaccines and Emerging Technologies - VACCINE CONGRESS 2026 (Japan)
- Next-Generation Vaccine Platforms - Vaccine Immunology 2026 (Canada)
- Next-Generation Vaccine Technologies - Vaccines R&D 2027 (France)
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors - Vaccine Immunology 2026 (Canada)
- One Health Approach to Vaccine Development - Vaccine Immunology 2026 (Canada)
- Pandemic Preparedness and Response - Vaccine Immunology 2026 (Canada)
- Pandemic Preparedness and Vaccine Development - Vaccines R&D 2027 (France)
- Pediatric and Adult Immunization - Vaccines R&D 2027 (France)
- Personalized Vaccinology and Precision Immunization - VACCINE CONGRESS 2026 (Japan)
- Precision Immunology and Personalized Vaccines - Vaccines R&D 2027 (France)
- Public Health and Global Immunization - Vaccine Immunology 2026 (Canada)
- Public Health and Immunization Policy - VACCINE CONGRESS 2026 (Japan)
- Regulatory Affairs and Vaccine Approval Systems - VACCINE CONGRESS 2026 (Japan)
- The Economics of Vaccination - Vaccine Immunology 2026 (Canada)
- Therapeutic Vaccines - Vaccines R&D 2027 (France)
- Translational Immunology - Vaccines R&D 2027 (France)
- Vaccine Adjuvants and Delivery Systems - Vaccines R&D 2027 (France)
- Vaccine Delivery Systems and Formulations - VACCINE CONGRESS 2026 (Japan)
- Vaccine Design and Molecular Biology - VACCINE CONGRESS 2026 (Japan)
- Vaccine Discovery and Development - VACCINE CONGRESS 2026 (Japan)
- Vaccine Hesitancy and Public Trust - Vaccine Immunology 2026 (Canada)
- Vaccine Manufacturing and Quality Control - Vaccines R&D 2027 (France)
- Vaccine Production and Global Supply Chains - Vaccine Immunology 2026 (Canada)
- Vaccine Research and Development - Vaccines R&D 2027 (France)
- Vaccine Research and Development - Vaccine Immunology 2026 (Canada)
- Vaccine Safety and Adverse Event Monitoring - Vaccine Immunology 2026 (Canada)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2026 (Japan)
- Vaccine Safety, Efficacy & Pharmacovigilance - Vaccines R&D 2027 (France)
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring - Vaccine Immunology 2026 (Canada)
- Vaccine-Induced Immunity and Duration of Protection - Vaccine Immunology 2026 (Canada)
- Viral and Bacterial Vaccine Research - VACCINE CONGRESS 2026 (Japan)
